We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App





Using CLEIA for Screening and RT-PCR for Confirmation Increases Accuracy of COVID-19 Diagnosis, Finds New Study

By LabMedica International staff writers
Posted on 21 May 2021
Print article
Image: The Lumipulse G600II instrument (left) and the Lumipulse® SARS-CoV-2 Ag kit (right), both manufactured by Fujirebio, which were used in this study for the quantification of SARS-CoV-2 in saliva samples (Photo courtesy of Shinichi Fujisawa)
Image: The Lumipulse G600II instrument (left) and the Lumipulse® SARS-CoV-2 Ag kit (right), both manufactured by Fujirebio, which were used in this study for the quantification of SARS-CoV-2 in saliva samples (Photo courtesy of Shinichi Fujisawa)
Scientists have shown that an antigen-based test for quantifying SARS-CoV-2 in saliva samples is simple, rapid, and more conducive for mass-screening, suggesting that combined CLEIA and RT-PCR testing on saliva samples increases the accuracy of diagnosis.

A team of scientists from Hokkaido University (Hokkaido, Japan) used a novel antigen-based kit, Lumipulse SARS-CoV-2 Ag kit (Lumipulse), developed by Fujirebio Europe (Ghent, Belgium) to quantitatively measure the viral antigen in biological samples within 35 minutes. The team used the antigen kit to detect SARS-CoV-2 in saliva samples, and assess the efficiency and accuracy of the test compared to RT-PCR. Their findings show that the antigen detection kit, which is used to perform chemiluminescent enzyme immunoassay (CLEIA), can rapidly detect SARS-CoV-2 with good accuracy in these samples.

The scientists tested 2056 individuals from three cohorts: patients with clinically confirmed COVID-19, individuals who had contacted patients with COVID-19, and individuals tested on arrival at Tokyo and Kansai International Airports. Saliva samples were collected from all individuals and used for RT-PCR tests as well as CLEIA using Lumipulse. The results of both were compared to determine the usefulness of CLEIA. The scientists found that CLEIA is a reliable test, as it correlates well with RT-PCR. CLEIA alone can be used to detect SARS-CoV-2 within an hour; however, using CLEIA for screening and RT-PCR for confirmation increases the accuracy of diagnosis.

The benefit of using saliva samples is the ease of collection: it is quick and can be collected by the individuals being tested, reducing the risk that healthcare workers are exposed to the virus. Furthermore, self-collection of saliva allows multiple samples to be collected simultaneously for expeditious screening of visitors at large gatherings. Combined CLEIA and RT-PCR testing on saliva samples has already been implemented at Japanese airport quarantines, and the scientists have recommended adopting it at a wider scale to rapidly screen for SARS-CoV-2.

Related Links:
Hokkaido University
Fujirebio Europe


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.